Ge Long Hui A P P·2026-02-27 09:48Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Philippines Food and Drug Administration for its Pregabalin capsules, allowing the product to be marketed [1] Group 1: Product Approval and Indications - Pregabalin capsules are primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunctive treatment for epilepsy [1] - The product development for Pregabalin capsules was completed by Changzhou Pharmaceutical Factory in October 2019 [1] Group 2: Regulatory Approvals Timeline - The Pregabalin capsules received approval from the U.S. Food and Drug Administration in July 2021 [1] - The product obtained a drug registration certificate in Thailand in June 2025 and in Singapore in January 2026 [1] Group 3: Investment in R&D - The company has invested approximately RMB 2.19 million in research and development for the product's market entry in Southeast Asia, which includes Thailand, Singapore, Malaysia, and the Philippines [1]